Hualan Biological Vaccine Inc.

Equities

301207

CNE1000058J9

Pharmaceuticals

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
23.55 CNY +1.73% Intraday chart for Hualan Biological Vaccine Inc. -6.55% -15.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Certain A Shares of Hualan Biological Bacterin Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024. CI
Hualan Biological Bacterin Inc. has Changed its Name to Hualan Biological Vaccine Inc CI
Hualan Biological Bacterin Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hualan Biological Bacterin Inc.(XSEC:301207) added to S&P Global BMI Index CI
Hualan Biological Bacterin Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hualan Biological Bacterin Inc. Announces Implementation of Final Profit Distribution Plan of A Shares for 2022, Payable on 07 June 2023 CI
Hualan Biological Bacterin Inc. Approves Cash Dividend for the Year 2022 CI
Hualan Biological Bacterin Inc. Announces Board Elections CI
Hualan Biological Bacterin Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hualan Biological Bacterin to Return to Profit in Q1 MT
Hualan Biological Bacterin Inc. Proposes Final Cash Dividend for 2022 CI
Hualan Biological Bacterin Gets Certification for Tetanus Vaccine MT
Certain A Shares of Hualan Biological Bacterin Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2023. CI
Hualan Biological Bacterin Registers Freeze-Dried Human Rabies Vaccine MT
Hualan Biological Bacterin Inc.(SZSE:301207) added to Shenzhen Stock Exchange Component Index CI
Hualan Biological Bacterin Inc.(SZSE:301207) added to Shenzhen Stock Exchange Component A Share Index CI
Hualan Biological Bacterin Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
China's Sept factory activity set for third straight monthly contraction:Reuters poll RE
Hualan Biological Bacterin Inc. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hualan Biological Bacterin Inc. Announces Final Dividend on Share A for 2021, Payable on June 16, 2022 CI
Hualan Biological Bacterin Inc. Approves Cash Dividend for the Year 2021 CI
Hualan Biological Bacterin Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chart Hualan Biological Vaccine Inc.
More charts
Hualan Biological Vaccine Inc, formerly Hualan Biological Bacterin Inc, is a China-based company principally engaged in the research, development, production and sales of human vaccines. The Company's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The Company's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The Company's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
23.55 CNY
Average target price
37.89 CNY
Spread / Average Target
+60.91%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Hualan Biological Vaccine Inc. - Shenzhen S.E.
  4. News Hualan Biological Vaccine Inc.
  5. Hualan Biological Bacterin Registers Freeze-Dried Human Rabies Vaccine